Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ARGX-110 |
Trade Name | |
Synonyms | JNJ-74494550|Cusatuzumab |
Drug Descriptions |
Cusatuzumab (ARGX-110) is a monoclonal antibody that targets CD70, resulting in inhibition of CD70-CD27-mediated signaling and enhanced immune response against CD70-expressing tumor cells (PMID: 28765328, PMID: 24492296, PMID: 32601337). |
DrugClasses | |
CAS Registry Number | 1864871-20-4 |
NCIT ID | C106116 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ARGX-110 | ARGX-110 | 0 | 0 |
ARGX-110 + Azacitidine | ARGX-110 Azacitidine | 0 | 3 |
ARGX-110 + Azacitidine + Venetoclax | ARGX-110 Azacitidine Venetoclax | 0 | 2 |
ARGX-110 + Decitabine | ARGX-110 Decitabine | 0 | 0 |
ARGX-110 + Venetoclax | ARGX-110 Venetoclax | 0 | 1 |